Chief Executive Officer

Dr. Sherif joined Oculis from Novartis where he served as Entrepreneur in Residence at Novartis Venture Fund during 2017. Prior to this, he held senior positions in global business development both at Alcon, where he was Region President of Europe, Middle East and Africa, and Novartis Pharmaceuticals, where he served as President of Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles as Head of Transplant and Infectious Disease for Latin America, and Head of the Novartis Vaccines and Diagnostics Division for Latin America.

Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a Specialized Master’s degree in Medical Management.

Vice President of Pharmaceutical Development and Iceland Site & Lab Head
Gudrun M. Asgrimsdottir joined Oculis in 2010 from GlaxoSmithKline in Reykjavik where she served as Business Unit Manager. Since joining Oculis, Ms. Asgrimsdottir has had management roles, currently holding the position of VP Pharmaceutical Development. Ms. Asgrimsdottir received a M.Sc. degree in pharmacy from the University of Iceland in 1997. Upon completing her studies, Ms. Asgrimsdottir joined the R&D department of Omega Farma ehf. where she was primarily responsible for analytical method development. In year 2000 she worked for GlaxoWellcome in the UK. Ms. Asgrimsdottir had the role of a clinical pharmacist in the UK for 4 years and did a diploma in hospital pharmacy from University of London in 2004. Ms. Asgrimsdottir is a co-author of 8 published papers in peer reviewed journals.
Vice President,
Global Clinical Development
Dr. Bingaman brings more than 20 years of pharmaceutical experience in discovery research and clinical development in the ophthalmology area. Before Oculis, David had served since 2011 as Senior Director, Head of Retina Development at Panoptica, which was developing a topical ocular treatment for neovascular AMD and diabetic retinopathy. Prior to Panoptica, he held several leadership roles with Alcon Research, moving from Discovery to Development as his teams’ programs were elevated into first-in-man trials. David is a board-certified member and diplomate of the American College of Veterinary Ophthalmologists. He completed his residency in Ophthalmology at Purdue University, and obtained his PhD through a joint program at Purdue and as a Retina Research Fellow in the Dept. of Ophthalmology at Indiana University. His Doctor of Veterinary Medicine (D.V.M.) and his Bachelor of Science (B.S.) in Veterinary Science degrees were obtained from the College of Veterinary Medicine at Washington State University.
Chief Financial Officer (CFO)
Ms. Cheung has 20 years of financial and general management experience at emerging growth life science companies. She joins Oculis from the NASDAQ-listed company Anika Therapeutics, Inc. where she was CFO from 2013 to 2020. During her tenure, she played a vital role in redefining and executing the company’s mission, vision and long-range financial-operational targets; supported and enabled U.S. launches of key therapeutics products; and executed on three strategic acquisitions. Prior to Anika, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Ms. Cheung began her career in the technology audit practice at PricewaterhouseCoopers. She holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as CPA in Massachusetts.
Vice President of Strategic Marketing and Business Development and Licensing
Mrs. Gauthier has 18 years of operational experience across a diverse range of therapeutic areas and healthcare sectors. She joined Oculis in 2018 from Pharmascience, where she was Commercial Head for Pendopharm, branded products division of Canadian based Pharmascience. Prior to Pharmascience, Mrs. Gauthier spent more than 10 years with Novartis Canada where she held several commercial positions of increasing responsibility, culminating in National Sales Associates. Her consolidated experience and knowhow span over complimentary disciplines – sales, marketing, market access, analytics, business development, and communication, providing her with a 360 ° overview of commercialization. She holds a Bachelor of Business Administration degree in Finance and Marketing from the University of Quebec in Montreal, an M.Sc. in Administration specialized in marketing from HEC Montreal, where she returned as lecturer. She was also certified in 2014 as Project Management Professional (PMP) by the Project Management Institute. Strong advocate for social involvement and believing in giving back to the community, Mrs Gauthier takes great pride in being one of the five founding members of Women Leaders in Pharma, association which aims at empowering women in the pharmaceutical industry; she also held different roles on committees and as a volunteer. She currently serves as a non-executive member of the EPFL Innovation Park Foundation Board.
Chief Development Officer
Dr. Jacobs brings to Oculis more than 20 years of leadership experience in drug development. He joins us from Osmotica Pharmaceuticals, where he was Vice-President of Clinical Development and Medical Affairs since 2017. During his tenure, in addition to leading the clinical programs from phase I to IV in several therapeutic areas including ophthalmology, he was a key contributor to successful FDA submissions and market approvals, a key experience.  Prior to his role at Osmotica, Dr. Jacobs held drug development leadership roles at Daiichi-Sankyo Pharmaceuticals, Aptalis Pharmaceuticals, Johnson & Johnson and King Pharmaceuticals.
Chief Strategy Officer
Mr. Jóhannesson joined Oculis in 2015 from Straumur Investment Bank where he served as Managing Director Corporate Finance. Prior to joining Straumur in 2015, he worked for Islandsbanki, and its predecessor Glitnir Bank, in Corporate Finance and Business Development. He has broad sector experience, having managed and advised on transactions within multiple industries, including pharmaceuticals, venture capital, energy, financials, and various manufacturing industries. Mr. Jóhannesson’s transaction experience includes, IPOs, private placements, M&A and restructurings. Mr. Jóhannesson has a B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil in Management Science from the University of Cambridge and is a certified securities broker in Iceland.
MSc. MPharm, Ph.D.
Chief Research and Technology Officer,

Dr. Loftsson is a leading scientist in the field of nanoparticle drug delivery, in particular cyclodextrin-based formulations. He has served as an advisor to many of the global pharmaceutical companies on drug formulations and IP rights. Dr. Loftsson co-founded and served as CEO of the biotechnology company Cyclops ehf. from 1994 until it was acquired by DeCode Genetics in 2000. At that time, he also took on the role of scientific advisor at Decode Genetics, until 2004. Dr. Loftsson received an MS degree in Pharmacy from the University of Copenhagen, School of Pharmaceutical Sciences and MS and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas, Department of Pharmaceutical Chemistry. He has served as Assistant, Associated and full Professor on the Faculty of Pharmaceutical Sciences, University of Iceland for over 35 years. Dr. Loftsson has authored and co-authored more than 220 peer-reviewed papers in addition to a couple of books and a number of book chapters. He is a fellow of the AAPS and is on the editorial boards of the Journal of Pharmaceutical Sciences, International Journal of Pharmaceuticals, Journal of Drug Delivery Science and Technology, Die Pharmazie, and the Journal of Pharmacy and Pharmacology. In 2014, Dr. Loftsson was recognized as one of the World’s Most Influential Scientific Minds by Thomson Reuters.

Vice President, Technology & Pharmaceutical Sciences

Dr. Pilotaz joins Oculis with more than 20 years’ experience in innovation of global sterile health products in both pharmaceutical and medical device industries, including 15 years in the Ophthalmology sector specifically. Most recently, he was Senior Director and Head of CMC and Pharmaceutical Operations at Nicox S.A. in charge of several outstanding ophthalmic development projects for the USA market. He has previously worked for Becton Dickinson and Laboratoires Thea with multiple incremental leadership positions in the R&D field.

Dr. Pilotaz completed a doctorate degree in pharmacy from the Grenoble school of pharmacy and he has a noteworthy experience in both intellectual property, project management, device design and marketing. He has an extensive track record in sterile drug design, development, industrialization and registration. He is co-author in 5 formulation patents for topical ophthalmic drugs and successfully contributed to multiple drugs commercialized in both Europe and USA.

Chief Medical Officer
Dr. de Souza Lima joins Oculis with more than 15 years of experience in the pharmaceutical, medical device and global healthcare sectors. Before Oculis, she served as Vice President, Head Global Medical Affairs for the global ophthalmology franchise at Shire. She has also worked at Novartis, Pfizer, Baush+Lomb and Ancile Pharmaceuticals, in senior global and US-focused medical and clinical development leader roles. She is an ophthalmologist by training and also completed a clinical research fellowship at the University of California, San Diego, and received a Master of International Public Policy (MIPP) from Johns Hopkins University.
Chief Innovation Officer,
Dr. Stefánsson is a leading physician in the field of diabetic eye disease and diabetic eye screening. Dr. Stefánsson has co-founded four biotechnology firms in addition to Oculis, including Cyclops ehf. which was acquired by DeCode Genetics in 2000. He contributes to a number of ophthalmological publications either as chief editor or on the editorial board. Dr. Stefánsson was knighted by the President of Iceland in 2007 and received a number of awards in science and ophthalmology, such as Iceland’s highest award in science in 2008 and the gold medal of the European Academy of Ophthalmology in 2014 among many other honours. Dr. Stefánsson has published more than 300 peer-reviewed international publications, more than 400 abstracts, numerous book chapters and patents. Dr. Stefánsson received a degree in medicine from the University of Iceland Medical School and a Ph.D. in physiology from Duke University followed by a residency and faculty position at Duke. He has served as Vice Dean and Dean of the Faculty of Medicine at the University of Iceland and served as Professor and Chair of the Department of Ophthalmology at the National University Hospital in Iceland since 1993.